1 week Ago By Defense World Staff
Bank of Montreal Can purchased a new stake in shares of BioVie Inc. ( NASDAQ:BIVI – Free Report ) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 50,000 shares of the company’s stock, valued at approximately $100,000.
Bank of Montreal Can owned 0.28% of BioVie at the end of the most recent reporting period. Other institutional investors also recently bought and sold shares of the company.
Prosperity Wealth Management Inc. purchased a new position in shares of BioVie during the 4th quarter worth approximately $63,000. Sanders Morris Harris LLC bought a new stake in shares of BioVie during the fourth quarter valued at approximately $85,000.
Drive Wealth Management LLC bought a new stake in shares of BioVie during the fourth quarter valued at approximately $120,000. Finally, Geode Capital Management LLC grew its stake in BioVie by 223.3% in the fourth quarter.
Geode Capital Management LLC now owns 123,408 shares of the company’s stock worth $247,000 after purchasing an additional 85,234 shares during the period. 4.59% of the stock is owned by institutional investors.
Analysts Set New Price Targets Separately, Brookline Capital Management upgraded shares of BioVie to a “strong-buy” rating in a report on Tuesday, March 18th. BioVie Stock Performance Shares of NASDAQ BIVI opened at $0.84 on Friday.
The company has a 50 day simple moving average of $1.04 and a two-hundred day simple moving average of $1.89.
BioVie Inc. has a fifty-two week low of $0.62 and a fifty-two week high of $7.
50. The company has a market capitalization of $15.50 million, a price-to-earnings ratio of -0.
09 and a beta of 0.64. BioVie ( NASDAQ:BIVI – Get Free Report ) last posted its quarterly earnings data on Tuesday, February 11th.
The company reported ($0.46) earnings per share for the quarter. About BioVie ( Free Report ) BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States.
Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. See Also Five stocks we like better than BioVie How to Short a Stock in 5 Easy Steps Markets Think Robinhood Earnings Could Send the Stock Up What is Forex and How Does it Work? Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Golden Cross Stocks: Pattern, Examples and Charts AT&T: Subscriber Growth & Buybacks Signal Bullish Turnaround Want to see what other hedge funds are holding BIVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioVie Inc.
( NASDAQ:BIVI – Free Report ). Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter .
.
